Venture Portfolio - Ivantis


Key Figures

  • 2007
    Creation Date
  • 2017
    Investment Date
  • 2022
    Exit Date
  • Mérieux Participations 2
    Fund Name

Company Presentation

Ivantis has developed the Hydrus™ Microstent, the world’s first “intracanalicular scaffold” for the treatment of primary open angle glaucoma (POAG).

The Hydrus procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions. Roughly the size of an eyelash, the Hydrus Microstent is made from a super-elastic, biocompatible alloy (nitinol®), which is a well-proven biomaterial used in over 1 million implants in a variety of medical devices to date.

Exit Date: 2022


38 Discovery - Suite 150 - CA 92618 Irvine - USA